{"type":"trials","record":{"id":87138,"source_id":"isrctn","external_id":"ISRCTN76889861","title":"An observational study following patients newly diagnosed with neovascular or 'wet' Age-related Macular Degeneration (AMD) looking at the changes within the eye both before and after treatment with anti-VEGF injection therapy","brief_summary":"Age-related macular degeneration (AMD) is the commonest cause of blindness in the retired western world population. Anti-Vascular Endothelial Growth Factor (Anti-VEGF) injectable treatment has had a significant impact on reducing the levels of blindness and restoring part of the visual loss experienced by individuals who have the less common, but more aggressive, ‘wet’ form of Age-related Macular Degeneration (AMD) or neovascular AMD (nvAMD). However, scarring, tissue loss and abnormal tissue formation (fibrosis and atrophy) beneath the crucial light sensitive part of the eye, the macula, limits the visual improvement that may be achieved for a patient. The late stage characteristics of fibrosis and atrophy of the outer retina remain the key pathological element associated with severe visual loss. New treatments are being developed that reduce this scar tissue formation on the assumption that better visual outcome with treatment of wet AMD may be possible. In particular there is a need to study whether it is possible to predict this tissue formation and/or response. At present there is no long term data on the development and progression of these forms of abnormal tissue. Being ab…","overall_status":"Completed","phases":[],"study_type":"Observational","sponsor":"York Teaching Hospital NHS Foundation Trust","enrollment":431,"countries":["United Kingdom","England","Northern Ireland"],"start_date":"2016-04-19","completion_date":"2022-02-07","last_update_date":"2023-10-17","source_url":"https://www.isrctn.com/ISRCTN76889861","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T03:46:39.792962+00:00","last_seen_at":"2026-09-25T03:46:39.551+00:00","metadata":{"sex":"All","age_range":"Adult","comparator":null,"attribution":"Source: ISRCTN ISRCTN76889861; retrieved 2026-09-25","interventions":["Other"],"reuse_license":"Registry contribution CC BY 4.0; generated metadata CC0","registry_source":"ISRCTN","outcome_measures":["1. Incidence of fibrosis and sub retinal highly reflective material (SHRM) over 12 months post-conversion in the initia…","1. Mean VA and change from baseline to conversion in both eyes (Snellen scale) 2. Mean VA and change from conversion to…"],"design_description":"Observational","source_has_results":false},"controlled_terms":["Neovascular age-related macular degeneration","FASBAT is an observational extension to the EDNA study. As such only patients who have already been consented to EDNA w…","Study website","Other"],"relevance_confidence":100,"source_quality_score":98,"freshness_score":65,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T03:46:42.633202+00:00","duplicate_cluster_key":"id:isrctn76889861","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2016-04-19 to 2022-02-07","comparator":null,"confidence":"structured-source","population":"All · Adult","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T03:46:39.576Z","intervention":["Other"],"participants":431,"study_design":"Observational","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["1. Incidence of fibrosis and sub retinal highly reflective material (SHRM) over 12 months post-conversion in the initia…","1. Mean VA and change from baseline to conversion in both eyes (Snellen scale) 2. Mean VA and change from conversion to…"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as Observational."],"matched_fields":["title","abstract","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ISRCTN Registry","homepage_url":"https://www.isrctn.com/"}},"canonical_url":"https://www.immortal.life/trials/87138","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}